7. Affirmed. The case is subject to the Private Securities Litigation Reform Act (PSLRA) which
was designed “to curb abuse in private securities lawsuits.” The Act mandates a more stringent
pleading standard for securities fraud actions, especially for scienter requirements. Other courts
agree that “plaintiffs can adequately plead scienter by setting forth facts raising a ‘strong
inference’ of intentional or reckless misconduct.” Plaintiffs have failed to show such recklessness
8. The SEC was correct that Gebhart could be barred for life. He acted recklessly, making false
statements promoting the security when he had no basis for doing so. As a professional, he could
not rely on the word of a friend, so there was scienter present and securities fraud existed. He did
Chapter 19: Consumer Protection
Answers to Select Case Questions
2. The Colorado Supreme Court remanded for new trial. It held that the first trial finding that the
drug caused the plaintiff’s injuries was sufficiently supported by the evidence. It is up to the jury
to determine the facts, the credibility of the witnesses, and weigh the evidence. Their finding in
that regard is not upset. The court cited the California supreme court which held that the jury
may find “a product is defective in design if 1) the plaintiff proves that the product failed to
perform as safely as an ordinary consumer would expect when used in an intended or reasonably
foreseeable manner, or 2) the plaintiff proves that the product’s design proximately caused injury
and the defendant fails to prove, in light of the relevant factors, that on balance the benefits of the
4. Yes, deceptive. “No reasonable fact finder could conclude that the solicitation was not likely to
deceive consumers acting reasonably under the circumstances.” Most people had no idea they